Symbol | Exchange | Currency |
---|
Provention Bio Inc. (NASDAQ:PRVB) reported Q2 EPS of ($0.46), $0.04 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $746 thousand versus the...
Provention Bio Inc. (NASDAQ:PRVB) reported Q1 EPS of ($0.35), $0.11 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $580 thousand versus the...
As of late, it has definitely been a great time to be an investor in Provention Bio, Inc. (NASDAQ:PRVB) . The stock has moved higher by 11.7% in the past month, while it is also...
Advanced Micro Devices, Inc. (AMD) Advanced Micro Devices, Inc. (NASDAQ:AMD) was ready to break out around the 28-29 area, I said your target is 33-34. It was up 82 cents, or 2.5%,...
salesforce.com, inc.’s (NYSE:CRM) shares decreased 5.3% after the company announced plans to acquire Tableau Software, Inc. (NYSE:DATA) in an all-stock deal worth $15.3...
Provention Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on intercepting and preventing immune-mediated diseases. The Company's product pipeline includes PRV-031 (teplizumab), PRV-3279, PRV-015 (ordesekimab) and PRV-101. Teplizumab is a humanized, anti-CD3 monoclonal antibody (mAb) for the delay of clinical type 1 diabetes (T1D) in at-risk individuals and for patients with newly diagnosed T1D. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins, CD32B and CD79B, for the treatment of systemic lupus erythematosus (SLE) and for the prevention of immunogenicity of biotherapeutics, such as those used in gene therapy. Ordesekimab is a human anti-interleukin 15 (IL-15) mAb for the treatment of gluten-free diet non-responsive celiac disease (NRCD). PRV-101 is a coxsackievirus B (CVB) vaccine to prevent acute CVB infections and, in those patients at-risk, to prevent the CVB-triggered autoimmune damage to pancreatic beta-cells.
Average | 19.714 (+128.519% Upside) |
High | 30.000 |
Low | 15.000 |
Price | 8.627 |
No. of Analysts | 7 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Buy | Sell | Sell | Strong Buy |
Technical Indicators | Strong Buy | Strong Buy | Buy | Strong Sell | Strong Buy |
Summary | Strong Buy | Strong Buy | Neutral | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
39.08 | 39.73 | 38.33 | +2.79 | +7.69% | 34.99M | NYSE | |||
20.27 | 20.32 | 20.07 | +0.11 | +0.55% | 14.57M | NYSE | |||
35.31 | 35.33 | 35.00 | +0.01 | +0.04% | 18.19M | NYSE | |||
143.80 | 143.91 | 142.28 | +0.80 | +0.56% | 31.52M | NASDAQ | |||
171.90 | 173.75 | 162.78 | +5.24 | +3.15% | 153.47M | NASDAQ | |||
72.57 | 73.93 | 72.13 | +0.44 | +0.61% | 683.43K | NASDAQ | |||
173.60 | 173.88 | 171.43 | -0.60 | -0.34% | 7.97M | NYSE | |||
41.99 | 42.00 | 41.99 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
148.87 | 149.88 | 147.52 | +1.81 | +1.23% | 19.77M | NASDAQ | |||
52.13 | 52.16 | 51.63 | +0.38 | +0.72% | 8.58M | NYSE | |||
13.65 | 13.71 | 13.19 | +0.35 | +2.63% | 349.27K | NASDAQ | |||
143.96 | 144.68 | 138.05 | +3.47 | +2.47% | 883.74K | NASDAQ | |||
5.20 | 5.23 | 4.85 | +0.21 | +4.21% | 285.31K | NASDAQ | |||
9.52 | 9.58 | 9.36 | +0.15 | +1.60% | 980.77K | NASDAQ | |||
74.67 | 75.00 | 72.03 | +2.22 | +3.06% | 45.03M | NASDAQ |